Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.64 |
| ▸ | BRAF | P15056 | 6/20 | 0.64 |
| ▸ | KDR | P35968 | 5/20 | 0.64 |
| ▸ | RET | P07949 | 4/20 | 0.64 |
| ▸ | ABL1 | P00519 | 3/20 | 0.64 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.64 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | KIT | P10721 | 2/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.64 |
| ▸ | FLT1 | P17948 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473807 | 0.89 | RAF1 (0.67) | RAF1BRAFKDRRETABL1 | |
| SCHEMBL6477661 | 0.87 | RAF1 (0.62) | RAF1BRAFKDRRETABL1 | |
| SCHEMBL6473119 | 0.87 | RAF1 (0.66) | RAF1BRAFKDRRETABL1 | |
| SCHEMBL6383539 | 0.87 | RAF1 (0.60) | RAF1BRAFKDRRETABL1 | |
| SCHEMBL6383620 | 0.87 | RAF1 (0.60) | RAF1BRAFKDRRETABL1 | |
| SCHEMBL6382308 | 0.86 | RAF1 (0.55) | RAF1BRAFKDRRETABL1 | |
| SCHEMBL6478678 | 0.85 | RAF1 (0.67) | RAF1BRAFKDRRETABL1 | |
| SCHEMBL12657051 | 0.83 | RAF1 (0.76) | RAF1BRAFKDRRETABL1 | |
| SCHEMBL16628088 | 0.82 | RAF1 (0.75) | RAF1BRAFKDRRETABL1 | |
| SCHEMBL16628057 | 0.82 | RAF1 (0.75) | RAF1BRAFKDRRETABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | claimed |
| EP-1608639-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | claimed |
| WO-2004078748-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | CCNC, UACA, SLC14A1 | RAF1 1822/4885BRAF 501/4885KDR 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.